Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr. Hideo Tamai

Onuma, Yoshinobu; Garg, Scot; Okamura, Takayuki; Ligthart, Jurgen; Geuns, Robert Jan van; Feyter, Pim J. de; Serruys, Patrick W.; Tamai, Hideo

doi:10.4244/eijv5ifa19

Cited by 28 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, BVS hold the potential to achieve the paradigm of vascular restoration therapy, restoring both vessel lumen and vascular function. [4][5][6][7] The aim of this review is to provide an overview of the current evidence supporting the use of BVS in clinical practice. In particular, we will discuss about randomized controlled trials and registries evaluating the clinical outcome of these devices, with a special focus on their application in patients with acute coronary syndrome and in specific lesion subsets (bifurcations, chronic total occlusions [CTO], and in-stent restenosis).…”

mentioning

confidence: 99%

Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease

Testa

Latib

Montone

et al. 2016

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Bioresorbable vascular scaffolds (BVS) represent a promising novel approach for the treatment of coronary artery disease. BVS promise to address some of the well-known limitations of current drug-eluting stents, while providing a transient scaffolding of the vessel to prevent acute vessel closure/recoil. Drug elution by BVS prevents neointimal proliferation in a similar fashion to drug-eluting stents, and complete bioresorption is associated with late vessel lumen enlargement, plaque regression, and restoration of vasomotion. Based on the pathophysiological reasons and on the results derived from clinical studies, BVS are increasingly being used in clinical practice. The aim of this review is to provide an overview of the current evidence supporting the use of BVS in clinical practice. In particular, we will discuss the randomized controlled trials and registries evaluating the clinical outcome of these devices, with a special focus on their application in patients with acute coronary syndrome and in specific lesion subsets (bifurcations, chronic total occlusions, and in-stent restenosis).

show abstract

mentioning

confidence: 99%

Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease

Testa

Latib

Montone

et al. 2016

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

show abstract

“…Desde el punto de vista angiográ-fico, la pérdida luminal tardía (LLL) fue de 0,91 ± 0,69 mm a los seis meses, lo que mejoró a 0,67 ± 0,45 mm a un año, y se mantuvo a los tres años de seguimiento (0,59 ± 0,50 mm). El ultrasonido intravascular (IVUS) mostró una reducción en el área luminal mínima a los seis meses (a partir de 5,44 ± 1,89 mm 2 después de la colocación de la plataforma a 3,64 ± 1,68 mm 2 ), que comenzó a aumentar en uno (4,06 ± 1,61 mm 2 ) y tres años (5,18 ± 2,09 mm 2 ) 26 . Aunque a corto y largo plazo los resultados de seguimiento fueron alentadores, este dispositivo no pudo progresar debido principalmente a la necesidad de catéte-res guía con mayor diámetro (8 F) para su implante, así como porque el contraste «climatizado» utilizado para el despliegue del dispositivo podía causar lesión vascular.…”

Section: Plataformas Biorreabsorbibles Disponibles En La Actualidadunclassified

Terapia de restauración vascular con plataformas biorreabsorbibles. La cuarta revolución

Echeverri¹,

Cabrales²

2014

Revista Colombiana de Cardiología

View full text Add to dashboard Cite

“…Recently, Nishio et al reported the long-term follow-up (>10 year) of an observational prospective study which enrolled 50 patients (63 lesions) implanted with Igaki-Tamai scaffolds (84 scaffolds) 40,41. The 10-year cumulative event-free survival rates of all-cause death, cardiac death, and MACE were 87%, 98%, and 50%, respectively, while the TLR rate was 16% at 1 year, 18% at 5 years, and 28% at 10 years.…”

Section: Currently Available Brssmentioning

confidence: 99%

Bioresorbable scaffolds in the treatment of coronary artery disease

Zhang¹,

Bourantas²,

Farooq³

et al. 2013

MDER

Self Cite

View full text Add to dashboard Cite

Drug-eluting stents have reduced the risk of in-stent restenosis and have broadened the application in percutaneous coronary intervention in coronary artery disease. However, the concept of using a permanent metallic endovascular device to restore the patency of a stenotic artery has inherited pitfalls, namely the presence of a foreign body within the artery causing vascular inflammation, late complications such as restenosis and stent thrombosis, and impeding the restoration of the physiologic function of the stented segment. Bioresorbable scaffolds (BRS) were introduced to potentially overcome these limitations, as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. Currently, several BRSs are available, undergoing evaluation either in clinical trials or in preclinical settings. The aim of this review is to present the new developments in BRS technology, describe the mechanisms involved in the resorption process, and discuss the potential future prospects of this innovative therapy.

show abstract

Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr. Hideo Tamai

Cited by 28 publications

References 4 publications

Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease

Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease

Terapia de restauración vascular con plataformas biorreabsorbibles. La cuarta revolución

Bioresorbable scaffolds in the treatment of coronary artery disease

Contact Info

Product

Resources

About